Table 6.
Clinical trials available on the ClinicalTrials.gov NIH U.S. National Library of Medicine website.
| Type of Cancer | Investigated Compound/Therapeutic Approach | ClinicalTrials.gov Identifier | Phase | The Aim of the Study | The Estimated Completion Date of the Clinical Trial |
|---|---|---|---|---|---|
| Metastatic melanoma stage III and IV | SX-682 (CXCR1/CXCR2 inhibitor) |
NCT03161431 | Phase 1 | Safety analysis of SX-682 alone and in combination with pembrolizumab | December 2023 |
| Multiple myeloma | MGTA-145 (CXCR2 agonist) |
NCT04552743 | Phase 2 | Efficacy analysis of MGTA-145 with plerixafor in mobilizing hematopoietic stem cells | 30 June 2022 |
| Metastatic pancreatic ductal adenocarcinoma | SX-682 (CXCR1/CXCR2 inhibitor) |
NCT04477343 | Phase 1 | Safety analysis of SX-682 in combination with nivolumab | 31 December 2024 |
| Metastatic melanoma, stage III and IV cutaneous melanoma | CXCR2-transduced autologous T cells | NCT01740557 | Phase 1 and 2 | Safety and clinical response analysis. | 31 January 2024 |